Understanding patient and provider preferences in management of metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Yazdanpanah, Omid
Benjamin, David Joseph
Vosoughi, Elham
Raad, Ali
Popal, Medina
Kongtim, Piyanuch
Mar, Nataliya
Rezazadeh, Arash
机构：
[1] Univ Calif Irvine, Div Hematol Oncol, Orange, CA 92668 USA
[2] Hoag Family Canc Inst, Newport Beach, CA USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Chao Comprehens Canc Ctr, Stern Ctr Canc Clin Trials & Res, Orange, CA USA
[5] Univ Calif Irvine, Orange, CA 92668 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16530
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Economic burden of adverse events in patients with metastatic renal cell carcinoma (mRCC).
    Hagiwara, May
    Borker, Rohit
    Oster, Gerry
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).
    Escudier, Bernard J.
    Iacovelli, Roberto
    Lanoy, Emilie
    Albiges, Laurence
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [43] FATIGUE IN METASTATIC RENAL CELL CARCINOMA (mRCC): CLINICIAN-REPORTED VS. PATIENT-REPORTED OUTCOME
    Rizzo, Mimma
    Carteni, Giacomo
    ANTICANCER RESEARCH, 2013, 33 (05) : 2337 - 2338
  • [44] The effect of information on preferences for treatments of metastatic renal cell carcinoma
    Mansfield, Carol
    Srinivas, Sandy
    Chen, Connie
    Hauber, A. Brett
    Hariharan, Subramanian
    Matczak, Ewa
    Sandin, Rickard
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (11) : 1827 - 1838
  • [45] A COMPARISON OF PREFERENCES FOR TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA
    Park, M. H.
    Lee, E. K.
    VALUE IN HEALTH, 2011, 14 (03) : A169 - A169
  • [46] Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC).
    Ebrahimi, Hedyeh
    Battle, Dena
    Zengin, Zeynep Busra
    Dizman, Nazli
    Meza, Luis A.
    Castro, Daniela V.
    Govindarajan, Ameish
    Mercier, Benjamin D.
    Chawla, Neal Shiv
    Chehrazi-Raffle, Alex
    Tripathi, Abhishek
    Liu, Sandy
    Vaishampayan, Ulka N.
    Staehler, Michael D.
    Pal, Sumanta Monty
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [47] Phase I study of IMP321 in metastatic renal cell carcinoma (MRCC)
    Escudier, Bernard
    Brignone, Chrystelle
    Grygar, Caroline
    Marcu, Manon
    Triebel, Frederic
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 885 - 885
  • [48] Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC).
    Tannir, Nizar M.
    Figlin, Robert A.
    Gore, Martin Eric
    Michaelson, Dror
    Motzer, Robert J.
    Porta, Camillo
    Rini, Brian I.
    Hoang, Caroline J.
    Lin, Xun
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [49] Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies
    Denouel, Angeline
    Heutte, Natacha
    Escudier, Bernard
    Kurtz, Jean-Emmanuel
    Dos Santos, Melanie
    Longato, Nadine
    Desrues, Laurence
    Dauchy, Sarah
    Lange, Marie
    Sevin, Emmanuel
    Rieux, Chantal
    Clarisse, Benedicte
    Castel, Helene
    Noal, Sabien
    Joly, Florence
    CLINICAL GENITOURINARY CANCER, 2018, 16 (05) : 369 - +
  • [50] Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Carducci, Michael Anthony
    Berger, Raanan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345